Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
Onco-Innovations Limited (ONNVF) pioneers next-generation cancer therapies through AI-driven drug discovery and nanoparticle delivery systems. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s oncology research advancements and strategic developments.
Access real-time announcements including clinical trial milestones, technology licensing agreements, and partnership updates with academic institutions. Our curated feed ensures you stay informed about key initiatives like SynoGraph AI platform enhancements and nanoparticle formulation breakthroughs without promotional bias.
Discover updates across critical categories: preclinical study results, intellectual property filings, OTCQB market disclosures, and collaborative research projects. Each update is vetted for relevance to the company’s mission of advancing precision oncology through cutting-edge science.
Bookmark this page for streamlined tracking of Onco-Innovations’ progress in developing therapies that target solid tumors while minimizing treatment toxicity. Verify time-sensitive information directly through official filings and press releases as you conduct due diligence.
Onco-Innovations (OTCQB:ONNVF) chaired Colorectal Cancer Canada’s fourth Catalysts roundtable, Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held virtually on December 2, 2025. The invitation-only session gathered ~20 senior leaders from industry, government, academic medicine, and clinical programs to discuss national scalability, data governance, interoperability, and transportable evidence for precision oncology.
Speakers included leaders from BC Cancer, University of Calgary, Inka Health, and others. Next steps: an internal roundtable report, a 2026 manuscript integrating series insights, advocacy materials on data innovation, and formation of working groups to advance AI-enabled precision medicine.
Onco-Innovations (OTCQB:ONNVF) announced on December 7, 2025 that it has engaged a U.S. investment bank to advise on a potential Nasdaq cross-listing and to evaluate a possible concurrent equity financing.
The advisory mandate covers analysis of listing requirements, regulatory and governance considerations, and capitalization strategies to support a U.S. cross-listing. The company said the structure and terms of any financing are not finalized and that there is no assurance a cross-listing or financing will be completed.
Onco-Innovations (OTCQB:ONNVF) attended the University of Alberta's 2025 Innovation Awards on November 21, 2025, highlighting its 2024 exclusive license of the PNKP Inhibitor Technology from the university.
The technology, developed over more than 15 years, is supported by nine issued patents and aims to sensitize cancer cells to chemotherapy and radiation by delaying DNA repair. Onco-Innovations said it is advancing preclinical development and IND-enabling studies toward clinical evaluation. The company also approved issuance of 60,000 Restricted Share Units to certain directors under its equity incentive plan.
Onco-Innovations (OTCQB:ONNVF) said Dalton Pharma Services began optimization and intermediate scale-up for its proprietary PNKP inhibitor A83B4C63 on November 20, 2025. The program advances from prior preclinical manufacturing to pilot-scale, non‑GMP synthesis using Dalton's FDA- and Health Canada‑approved Toronto facility.
Key activities include intermediary batches targeting approximately 500 g of precursor A83 and 1,000 g of precursor B4, analytical method qualification, ICH‑guided stability testing, and a formal safety and risk assessment to support future GMP production and IND‑enabling work toward Phase 1 studies.
Onco-Innovations (OTCQB:ONNVF) announced a pilot collaboration with Kuano to accelerate development of its PNKP Inhibitor Technology (A83B4C63) using AI, molecular modelling and Kuano's quantum-ready analytics.
The pilot runs through Q4 2025 and aims to deliver validated platform outputs, structural binding models, and mechanistic hypotheses to guide structure optimization, generative design, toxicity mapping, and preclinical candidate selection.
Onco-Innovations (OTCQB:ONNVF) announced that subsidiary Inka Health published a technical primer titled Transportability of Non-Local Real-World Evidence in the Journal of Clinical Evaluative Research on November 7, 2025. The primer outlines three foundational principles — consistency, positivity, conditional exchangeability — and describes statistical techniques (matching, weighting, standardization, bias analysis) to adapt non-local RWE for Health Technology Assessment.
Inka Health plans to integrate these methods into its SynoGraph platform to support cross-border oncology evidence use, especially for rare diseases with limited local data.
Onco-Innovations (OTCQB:ONNVF) provided a shareholder update outlining 2026 priorities, emphasizing a U.S. growth strategy and clinical translation.
Key 2025 milestones cited include the acquisition of Inka Health AI (Feb 2025), moving its stock listing to the Cboe Canada Market, partnerships with Dalton Pharma (May 2025), collaboration with the University of Alberta and Cross Cancer Institute (June 2025), an agreement with Nucro-Technics (July 2025), and a start-up agreement with Avance Clinical. The company says it is preparing for a Phase 1 clinical trial in 2026 and plans to pursue a U.S. stock exchange cross-listing in 2026 to broaden investor access and R&D engagement.
Onco-Innovations (OTCQB:ONNVF) appointed Jared Rushton to its Board of Directors, effective October 30, 2025, replacing Zachary Stadnyk.
Mr. Rushton brings over a decade of public markets experience in corporate development, strategic advisory and capital markets planning across mining, cannabis and biotech sectors.
The company also engaged MCS Market Communication Service GmbH for online marketing services through December 15, 2025 (or until budget exhaustion) and paid EUR 600,000 in consideration; no securities were issued to MCS. Services include Google Ads, native advertising, campaign creation, and analytics.
Onco-Innovations (OTCQB:ONNVF) closed a non-brokered private placement on October 27, 2025, issuing 1,428,570 units at $1.40 per unit for aggregate gross proceeds of $2,000,000. Each unit comprises one common share and one-half of one warrant; warrants are exercisable at $2.00 per share for 36 months. The company paid finders $119,999.94 and issued 85,714 warrants, and issued 14,286 administrative shares for services. Proceeds are for general corporate and working capital purposes, including operational, R&D and investor relations objectives. All securities are subject to a four-month-and-one-day statutory hold and are not registered for sale in the United States.
Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 1,428,572 units at $1.40 per unit to raise up to $2,000,000. Each unit includes one common share and one-half of a warrant, with each whole warrant exercisable at $2.00 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of shares sold and may pay finders' fees or issue finders' warrants on similar terms. Proceeds are for general corporate and R&D purposes. Closing is subject to regulatory approvals and issued securities carry a four-month-and-one-day hold. The company also appointed Christopher Gulka to the board, succeeding Graydon Bensler.
FAQ
What is the current stock price of Onco-Innovations (ONNVF)?
